BCTX
BriaCell Therapeutics Corp.8.70
-0.28-3.06%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
No earnings call transcript available
Key Stats
Market Cap
16.45MP/E (TTM)
-Basic EPS (TTM)
-33.87Dividend Yield
0%Recent Filings
8-K
BriaPro reports rising losses
BriaPro disclosed unaudited interim results for six months ended January 31, 2026, posting a $472K comprehensive loss on $433K R&D spend, up from $233K prior year; cash stays at $1 while related-party debt climbs to $1.6M. Post-period, it closed a deal on March 30 for BriaCell's sCD80 license, issuing shares worth C$1.18M for worldwide rights and $3M credit line, but going concern hinges on funding.
10-Q
Q2 FY2026 results
BriaCell ramped R&D spend 36% y/y to $12.7M for H1 FY2026 ended January 31, 2026, driving operating loss to $15.9M from $12.3M while net loss widened to $15.6M, narrowed by $243K financial income. Q2 operating loss edged up 5% y/y to $7.5M on Phase 3 Bria-IMT and Bria-OTS trial acceleration. Diluted EPS improved to $(6.58) from $(54.35) via share count expansion to 2.3M (derived). Cash swelled to $29.9M after $27.9M January offering, funding $15.7M operating burn. Cash fuels runway. Clinical delays loom.
8-K
Shareholders approve auditors, board
BriaCell Therapeutics held its annual meeting on March 5, 2026, where shareholders ratified MNP LLP as auditors, elected six directors including Dr. Jane Gross and Mr. Jamieson Bondarenko amid broker non-votes, and re-approved the omnibus equity incentive plan. Votes showed strong support yet broker non-votes hit 1,615,665 shares. Board continuity secured.
8-K
BriaCell transfers sCD80 to BriaPro
BriaCell Therapeutics transferred its exclusive sCD80 cancer therapy license to majority-owned subsidiary BriaPro via asset purchase agreement announced February 18, 2026. BriaPro issues 23,972,589 shares worth ~C$1.18M to BriaCell, boosting its stake to 78%, while BriaCell offers up to $3M credit facility. Closing targeted for March 12, 2026, pending disinterested shareholder approval and third-party valuation. Internal shift sharpens focus.
8-K
BriaCell closes $30M offering
BriaCell closed its $30 million public offering on January 15, 2026, selling 4.3 million common units and 1.0 million pre-funded units at $5.59 each. Warrants, exercisable at $6.93 for five years, trade as BCTXL. Funds target working capital and business advancement. Dilution hits existing holders hard.
BCAB
BioAtla, Inc.
0.76-0.01
BCLI
BrainStorm Cell Therapeutics In
0.58+0.03
BOLT
Bolt Biotherapeutics, Inc.
5.45+0.06
CELC
Celcuity Inc.
100.39-1.79
CNTX
Context Therapeutics Inc.
1.10-0.03
IMTX
Immatics N.V.
10.09+0.11
MRKR
Marker Therapeutics, Inc.
1.27-0.12
NWBO
Northwest Biotherapeutics, Inc.
0.25+0.01
SMMT
Summit Therapeutics Inc.
17.23-0.15
TGTX
TG Therapeutics, Inc.
30.79-0.62